28/03/2023
After a week of inspiring exchanges at World Evidence, Pricing and Access Congress, our minds are overloaded with fascinating insights and essential industry knowledge. Here’s a recap of invaluable takeaways we soaked up in this incredible event ⤵️
👉 Value-based procurement is becoming the driving force behind healthcare tendering processes, with pricing still seen as a significant factor in decision-making
👉 Health technology assessments examine clinical evidence, product safety and cost-effectiveness, and the proposed intervention's societal, legal, and ethical implications
👉 AI and machine learning could be used to predict clinical safety risk
👉 HTA outcomes and trends in healthcare need to improve the understanding of medical interventions
👉 Value-based procurement considers pricing as an essential determining factor
👉 Technology advancements can help address the orphan drug pricing problem
👉 A shift in market access thinking towards earlier research & development was suggested to allow for greater inclusion, diversity and equity in clinical trials for better future outcomes
👉 AI-based tools such as OpenAIs ChatGPT 3 & 4 and Google's Bard AI Chatbot have the potential to improve healthcare systems and procurement processes and limit inefficiencies
👉 AI could be used to combat challenges such as emerging diseases, antimicrobial resistance, drug discovery, ageing populations, rising chronic diseases and growing shortages in the healthcare workforce
Let us know what insights you gained, too — a big thank you to everyone who showed up and shared their wisdom. 💭 We’re looking forward to staying connected with you all. See you next year with more knowledge-exchange fun.🤝🚀
